Clinical Trial

Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The aim of the study to evaluate the safety and efficacy of Sacituzumab Tirumotecan in combination with osimertinib or as monotherapy for neoadjuvant treatment in patients with resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-02
Trial Details
NCT Number NCT07329322
Lead Sponsor Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Conditions Non-Small Cell Lung Cancer
Enrollment 60 participants
Start Date 2026-03-30
Primary Completion 2027-08-31 (estimated)
Study Completion 2032-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-11